It’s the right time to start your journey
TEMIXYS™ is a prescription medicine approved by the U.S. Food & Drug Administration (USFDA).
TEMIXYS™ is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and children weighing at least 77 pounds (35 kg).
TEMIXYS is a prescription medicine that is used in combination with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) in adults and children weighing at least 77 pounds (35 kg).
HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). TEMIXYS contains the prescription medicines lamivudine and tenofovir disoproxil fumarate.
Do not take TEMIXYS if you are allergic to lamivudine, tenofovir disoproxil fumarate, or any of the ingredients in TEMIXYS. See the end of Patient Information leaflet for a complete list of ingredients in TEMIXYS.
Please click here for full Prescribing Information, including Patient Information with important warnings.
What is the most important information I should know about TEMIXYS™?
TEMIXYS can cause serious side effects, including:
Worsening of hepatitis B infection. Your healthcare provider will test you for HBV and HIV before starting treatment with TEMIXYS. If you have Human Immunodeficiency Virus type 1 (HIV-1) and hepatitis B virus (HBV) infection, your HBV may get worse (flare-up) if you stop taking TEMIXYS. A “flare-up” is when your HBV infection suddenly returns in a worse way than before. Your healthcare provider will test you for HBV infection before you start treatment with TEMIXYS.
What are the possible side effects of TEMIXYS?
TEMIXYS may cause serious side effects, including:
New or worse kidney problems, including kidney failure.Your healthcare provider may do blood and urine tests to check your kidneys before and during treatment with TEMIXYS. Tell your healthcare provider if you get signs and symptoms of kidney problems, including bone pain that does not go away or worsening bone pain, pain in your arms, hands, legs or feet, broken (fractured) bones, muscle pain or weakness.
Changes in your immune system (Immune Reconstitution Syndrome) can happen when an HIV-1 infected person start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having new symptoms after starting your HIV-1 medicine.
Bone problems can happen in some children or adults who take TEMIXYS. Bone problems include bone pain, softening or thinning of bones, which may lead to fractures. Your healthcare provider may need to do tests to check your bones or your child's bones. Tell your healthcare provider if you have any bone pain, pain in your hands or feet, or muscle pain or weakness during treatment with TEMIXYS.
Too much lactic acid in your blood (lactic acidosis).
Too much lactic acid is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.
Severe liver problems.
In rare cases, severe liver problems can happen that can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.
Use with interferon and ribavirin-based regimens.
Worsening of liver disease that has caused death has happened in people infected with HIV-1 and hepatitis C virus who were taking antiretroviral medicines for HIV-1 and were also being treated for hepatitis C with interferon alfa with or without ribavirin. If you are taking TEMIXYS and interferon with or without ribavirin, tell your healthcare provider if you have any new symptoms.
Risk of inflammation of the pancreas (pancreatitis).
Children may be at risk for developing pancreatitis during treatment with TEMIXYS if they:
The most common side effects of TEMIXYS include:
rash / headache / pain / diarrhea / depression
Tell your healthcare provider right away if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TEMIXYS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before you take TEMIXYS, tell your healthcare provider about all of your medical conditions, including if you:
have liver problems, including hepatitis B or C virus infection.
have kidney problems, including end-stage renal disease (ESRD) that requires dialysis.
have bone problems, including a history of bone fractures.
are pregnant or plan to become pregnant. It is not known if TEMIXYS may harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with TEMIXYS.
Pregnancy Registry. There is a pregnancy registry for women who take TEMIXYS during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.
are breastfeeding or plan to breastfeed. Do not breastfeed if you take TEMIXYS.
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.
Some medicines interact with TEMIXYS. TEMIXYS may affect the way other medicines work, and other medicines may affect how TEMIXYS works. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
You can ask your healthcare provider or pharmacist for a list of medicines that interact with TEMIXYS.
Do not start taking a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take TEMIXYS with other medicines.
You should not take TEMIXYS if you also take: